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Abstract
Surfactant protein A (SP-A), the most abundant protein in the lung alveolar surface, has multiple activities, including surfactant-related
functions. SP-A is required for the formation of tubular myelin and the lung surface film. The human SP-A locus consists of two functional SP-A
genes, SP-A1 and SP-A2, with a number of alleles characterized for each gene. We have found that the human in vitro expressed variants, SP-A1
(6A2) and SP-A2 (1A0), and the coexpressed SP-A1/SP-A2 (6A2/1A0) protein have a differential influence on the organization of phospholipid
monolayers containing surfactant protein B (SP-B). Lipid films containing SP-B and SP-A2 (1A0) showed surface features similar to those
observed in lipid films with SP-B and native human SP-A. Fluorescence images revealed the presence of characteristic fluorescent probe-
excluding clusters coexisting with the traditional lipid liquid-expanded and liquid-condensed phase. Images of the films containing SP-B and SP-
A1 (6A2) showed different distribution of the proteins. The morphology of lipid films containing SP-B and the coexpressed SP-A1/SP-A2 (6A2/
1A0) combined features of the individual films containing the SP-A1 or SP-A2 variant. The results indicate that human SP-A1 and SP-A2 variants
exhibit differential effects on characteristics of phospholipid monolayers containing SP-B. This may differentially impact surface film activity.
© 2007 Elsevier B.V. All rights reserved.Keywords: Genetic variant; Interaction of surfactant protein and lipid; Organization of phospholipid monolayer; Surfactant protien A (SP-A); Surfactant protien B
(SP-B)1. Introduction
Pulmonary surfactant is essential for normal lung function.
Structurally, it is dynamic and a number of morphologic forms
have been characterized for surfactant. These, among others,
include lamellar bodies found both intracellularly and extra-
cellularly, and tubular myelin and the surface film found extra-
cellularly. Its composition is about 90% lipids and 10% proteins.Abbreviations:DPPC, 1,2-dipalmitoyl-sn-3-phosphocholine; CHO, Chinese
Hamster Ovary (CHO)-K1 cell line; LE phase, liquid-expanded phase; LC
phase, liquid-condensed phase; PG, L-α-phosphatidylglycerol (from egg PC,
sodium salt); SP-A, surfactant protein A; SP-B, surfactant protein B
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doi:10.1016/j.bbamem.2007.06.025The surfactant-associated proteins (SPs) include SP-A, SP-B, SP-
C, and SP-D. The primary lipid is dipalmitoylphosphatidylcho-
line (DPPC), which comprises over 40% of the material. Other
lipids present in relatively substantial amounts are unsaturated
phosphatidylcholine (PC), phosphatidylglycerol (PG), and chol-
esterol [1]. SP-A, an asialoglycoprotein of complex architecture,
plays an important role in the structure, metabolism, and the
surface-tension lowering activity of surfactant [2–7], host
defense [8–10], and in parturition, serving as a hormone [11].
The human SP-A locus consists of two functional genes,
SP-A1 and SP-A2, in opposite transcriptional orientation, and
a pseudogene between the SP-A1 and SP-A2 genes [12]. Both,
the cDNAs and the genomic sequences have been cloned and
characterized [13–15]. Based on nucleotide differences within
the coding region, more than 30 alleles (or variants) for both
genes have been characterized in part or fully [16,17]. Ten of
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of 0.01. Four of these are for SP-A1 (i.e. 6A, 6A2, 6A3, 6A4),
and six are for SP-A2 (i.e. 1A, 1A0, 1A1, 1A2, 1A3, 1A5). Some
of the nucleotide polymorphisms result in amino acid
substitutions [18], and collectively SP-A1 and SP-A2 variants
differ at 10 amino acid residues, including a cysteine at
position 85. Native SP-A is an octadecamer that consists of
six trimers, and it has been suggested that each trimer consists
of two SP-A1 and one SP-A2 gene products [19]. However,
the mRNA ratio of SP-A1 and SP-A2 differs from the 2:1
ratio proposed for protein structure [20], indicating that single
gene products may exist in homo-oligomeric structures.
Moreover, recent evidence indicates that the relative amounts
of SP-A1 and SP-A2 gene products differ as a function of
lung health status [21].
In vitro expressed single gene products of human SP-A1 or
SP-A2 have been shown to be functional, and with differences
in biochemical and biophysical properties, as well as in other
functions [22–26]. Previous findings on the expressed protein
products of the SP-A1 and SP-A2 alleles [24] have indicated
that the two gene products exhibit the following differences: in
oligomerization of the protein under appropriate conditions; in
the structural stability of their collagen domains, with the SP-A2
products being more stable than those of SP-A1; in ability to
cause aggregation of lipopolysaccharides and liposomal lipids,
with SP-A2 products being more potent in causing aggregation
than SP-A1 products. In addition, a number of SP-A variants
have been shown to associate with several pulmonary diseases
including respiratory distress syndrome in the prematurely born
infant [22,27–31]. A synergistic effect between SP-A and SP-B
variants in RDS susceptibility has also been observed [31–34].
SP-A and SP-B are necessary for the formation of tubular
myelin [5,6], and SP-A has been shown, in vitro, to have an
impact on the regional organization of phospholipid monolayers
containing SP-B or SP-C [35,36]. The question addressed in this
report is whether the two human SP-A1 and SP-A2 gene
products have a differential influence in the organization of
phospholipid monolayers, especially monolayers containing
phospholipids and the surfactant protein SP-B [36]. To explore
this, we studied the interaction of human in vitro expressed SP-
Avariants (i.e. the 6A2 of SP-A1, the 1A0 of SP-A2, and the co-
expressed 6A2/1A0 product of SP-A1/SP-A2) with SP-B, in
phospholipid monolayers. The SP-A variants used in the study
were expressed in vitro from stably transfected mammalian
Chinese Hamster Ovary (CHO) cells. The results indicated
differences between the two SP-A variants in their interaction
with SP-B.
2. Materials and methods
2.1. Experimental materials
DPPC and egg PG were obtained from Avanti Polar Lipids (Birmingham,
AL), and were used as received after verification of their purity by thin layer
chromatography. Water was deionized and doubly distilled, and the second
distillation being from dilute potassium permanganate solution. Other chemicals
were obtained from Fisher Scientific Co. (Ottawa, ON, Canada) or Sigma (St.
Louis, MO).2.2. Human SP-A1 and SP-A2 variants from in vitro expression CHO
cells
The mammalian Chinese Hamster Ovary (CHO)-K1 cell line (American
Type Culture Collection, Manassas, VA, Cat. CCL 61) was used as the host to
express human SP-A variants. The cell culture techniques and the culture media
were previously described [37]. Stably transfected CHO cell lines that
expressed human SP-A1 (6A2) or SP-A2 (1A0) were obtained through
transfection and selection, as described previously [37]. To express SP-A
variants, cells were grown to confluence in the growth medium with fetal
bovine serum, then the growth medium was removed and expression medium,
which did not contain fetal bovine serum but had 0.5 mM ascorbic acid, and
40 mg of proline per liter medium was added. The medium containing secreted
SP-A protein was harvested after 5 days in culture, and SP-A variants were
recovered and purified from the culture medium using mannose-affinity
chromatography, as described previously [26]. Purified SP-A was concentrated
using Amicon Centriprep-10 concentrators (Amicon, Beverly, MD).
2.3. Native human SP-A from BAL fluid
The native human SP-A was purified from BAL fluid obtained from
alveolar proteinosis patients using a butanol-extraction method as described
[38,39] with slight modification. In brief, after complete extraction of whole
BAL surfactant with butanol, the mixture was centrifuged at 5000×g at 15 °C
for 30 min and the supernatant, which contains the butanol, was discarded.
The pellet was then completely dried with a flux of nitrogen gas. The dry
pellet was homogenized in 24 ml of the OBG buffer (20 mM n-Octyl β-
D-Glucopyranoside, 10 mM HEPES, 150 mM NaCl, pH 7.4) and centrifuged
at 210,000×g at 15 °C for 30 min, and then the supernatant containing
detergent-soluble proteins and potential trace amount of butanol was
discarded. The above procedure was repeated twice. After a final pelleting,
the detergent-insoluble protein was dissolved in 5 ml of buffer (5 mM Tris/
HCl, pH 7.4) and dialyzed extensively for 48 h against 4 l of the same buffer
with four changes of buffer. The dialyzed solution was centrifuged at
155,000×g at 4 °C for 30 min and the supernatant containing SP-A was
collected and kept at −80 °C.
With regards to the potential surface activity of butanol that was used early
in the purification procedure, we have always been particularly cautious about
avoiding any effects of residual surface active material by diluting and
dialyzing our samples quite extensively. In this case, the butanol used in the
early step was removed immediately by centrifugation and pellet dryness
procedure. The pellet was then resuspended in 24 ml OBG buffer (see above)
and centrifuged to remove any contaminating trace of butanol (this procedure
was repeated 3 times). The final pellet was dissolved in 5 ml of buffer (see
above) and dialysed against 0.8×103 fold buffer with four changes of the
buffer. Therefore, the dilution factor is estimated to be about 1015. We have
never observed abnormal effects that we could attributed to butanol or other
materials in our studies with SP-A.
All procedures were performed at 4 °C or on ice. Protein concentration of
SP-Awas determined using the Micro-BCA method of Smith et al. [40] (Pierce,
Rockford, IL) with RNase A as a standard. SP-A was aliquoted and stored at
−80 °C, until use.
2.4. Porcine SP-A and porcine SP-B preparation
Porcine SP-A and SP-B were prepared as described before [41]. In brief, pig
lungs were lavaged with 150 mMNaCl, and the lavage was centrifuged at 800×g
for 10 min. The pellet was removed and the supernatant was centrifuged again at
7000×g for 60 min. The pellet was used for isolation of either SP-A or SP-B.
SP-A was obtained from the pellet by extraction with 1-butanol and further
purified as described above [38,42]. SP-B was prepared from the pellet using
chloroform–methanol as described previously [43,44].
2.5. Monolayer epifluorescence analysis
Monolayer fluorescencemeasurements were performed in the followingway.
DPPC or DPPC:eggPG (8:2, mol/mol) and SP-B were mixed in chloroform:
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Monolayers were formed by spreading of the lipid–protein mixture
containing 17 wt.% SP-B on subphases of 145 mM NaCl, 5 mM Tris,
5 mM CaCl2 (pH 6.9) in the presence of SP-A (subphase concentration
0.68 μg/ml). The apparatus used in these experiments has been described
previously [45]. A modified monolayer trough was employed to reduce the
subphase volume and surface area by about 10-fold from that of the original
trough in order to study the small amounts of gene products that were
available at subphase concentrations appropriate to those employed in
previous studies of SP-A in monolayers systems [35,36]. Experiments wereFig. 1. Image of monolayers of DPPC containing 17% SP-B spread over a subphase
pressures at which images were obtained are given at the sides of the figure. Three p
(bright regions, circles), lipid liquid-condensed (LC) phase (small black domains, a
regions, block arrows). The morphology of the DPPC monolayers containing SP-B a
and porcine SP-A in panel A.performed in a small Teflon trough with a volume of 12.5 ml [36], at a
temperature of 21–23 °C. The initial spreading surface pressure was about
5 mN/m. After spreading, 1 h was allowed for adsorption of SP-A to the
spread monolayers during which time the subphase was stirred continuously.
To increase the surface pressure of the films small aliquots of SP-B/DPPC
were added to the surface and 5 min were allowed for evaporation of solvent
and for equilibration of the films. At each surface pressure the monolayers
were observed through the fluorescence of NBD-PC which partitions into the
liquid-expanded (LE) phase of the lipid monolayer [36,46]. Each experiment
was repeated at least twice.of 0.68 μg/ml of porcine SP-A (panel A) and human SP-A (panel B). Surface
hases in the images were observed, including lipid liquid expanded (LE) phase
rrows), and surface clusters characteristic of SP-A and SP-B complexes (grey
nd human SP-A in panel B was similar to that of the lipid monolayers plus SP-B
Fig. 2. Images of films of DPPC: egg PG (8:2, mol/mol) containing 17% SP-B
spread over human SP-A at 0.68 μg/ml. Surface pressures are given at the side of
each image. In these images of monolayers of DPPC:eggPG plus SP-B spread
on human SP-A show that the interactions between SP-A and SP-B produced the
protein-rich phase (grey clusters, block arrows) in the monolayers regardless of
the presence of 20 mol% unsaturated PG.
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3.1. Effect of porcine SP-A in DPPC monolayers with porcine
SP-B
Fig. 1, panel A shows epifluorescence images at different
surface pressures of monolayers of DPPC and porcine SP-B
spread on subphases containing porcine SP-A. The images
show the presence of three phases: lipid liquid expanded (LE)
phase (bright regions, circles), lipid liquid-condensed (LC)
phase (small black domains, arrows), and surface clusters
characteristic of SP-A/SP-B complexes (grey regions, block
arrows). In similar experiments with SP-A and SP-B labeled
with two different fluorophores we have shown that the surface
clusters, seen as grey phase in the images, are specific for the
combination of SP-A and SP-B, and they are comprised of the
two proteins and possibly some lipids [36].
These control studies showed that the different methodology
used to form and compress the monolayer that was used in these
experiments gave results which were consistent with mono-
layers formed on a larger trough and compressed mechanically
using a ribbon barrier, the more “conventional” way to carry out
monolayer compression.
3.2. Effect of human SP-A in DPPC or DPPC:PG monolayers
with porcine SP-B
Fig. 1B shows images at different surface pressures of
monolayers of DPPC/SP-B spread on solutions of human SP-A.
A surface phase (grey clusters in the images, block arrows), in
addition to the conventional lipid LE and LC phases, is
detectable. The morphology of the DPPC monolayers contain-
ing SP-B and human SP-A was similar to that of the lipid
monolayers plus SP-B and porcine SP-A (Fig. 1A). These
experiments showed that human SP-A and porcine SP-B
formed the same type of protein-rich complexes as were seen
with porcine SP-A in previous studies [36].
Many of the previous studies on the SP-A and SP-B
interactions in monolayer experimental systems had been
carried out in the presence of DPPC plus 20% PG [36]. The
influence of PG on the interactions of human SP-A and porcine
SP-B was therefore investigated. Fig. 2 represents images of
monolayers of DPPC:eggPG (8:2, mol/mol) plus SP-B spread
on human SP-A. The data showed that the interactions between
SP-A and SP-B produced the protein-rich phase (grey clusters,
block arrows) in the monolayers regardless of the presence of 20
mol% unsaturated PG.
3.3. Effect of SP-A1 variant (6A2) in DPPC monolayers with
porcine SP-B
Fig. 3A and B shows images at different surface pressures
of two experiments with monolayers of SP-B/DPPC spread on
subphases containing SP-A1 variant (6A2). The images reveal
three characteristic features typical for the monolayers: a fine
network of grey phase (block arrows), which extended
throughout the LE phase, large protein-rich patches (largedark grey regions, stars), and LC phase (small black domains,
arrows). The SP-A1 molecules were likely localized in the
network in the lipid LE phase and in the large characteristic
patches seen in the monolayers. The distribution of the grey
network throughout the LE phase was different than any of the
images seen before with SP-A and SP-B in any of these
monolayer systems, suggesting that the 6A2 variant of SP-A1
had a different type or extent of interaction with SP-B, and
possibly lipids, than did “native” SP-A or the allele 1A0 of
SP-A2 protein (see below).
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porcine SP-B
Fig. 4A and B shows results at different surface pressures
from two experiments with monolayers of SP-B/DPPC spread
on subphases containing the protein product of allele 1A0 of
SP-A2. The morphology of the films was very similar to that
observed in the films containing combinations of SP-B and
porcine SP-A (Fig. 1A) or human SP-A (Figs. 1B and 2). In
this case, the probe-excluding phase (block arrows), which
was characteristic for the phospholipid monolayers containing
combinations of SP-B and native SP-A, co-existed with, but
was separate from, the lipid LE (bright regions, circles) and
LC (black domains, arrows) phases.
3.5. Effect of the coexpressed SP-A1/SP-A2 (6A2/1A0) protein
in DPPC monolayers with porcine SP-B
Fig. 5A and B represents images at different surface
pressures from two experiments with monolayers of SP-B/
DPPC spread on subphases containing the coexpressed SP-A1/
SP-A2 (6A2/1A0) protein. The morphology of the films
containing the coexpressed SP-A1/SP-A2 (6A2/1A0) protein
appears to combine features of the lipid–protein monolayers
containing SP-A1 (Fig. 3) and SP-A2 (Fig. 4). Large likely
protein-rich patches (stars), similar to those seen in the
monolayers spread on SP-A1 (Fig. 3) and a network of grey
phase (block arrows) extended throughout the LE phase in the
films containing the coexpressed SP-A1/SP-A2 (6A2/1A0)
protein. In some cases, however, the grey phase appeared to
segregate from the LE phase and regions of the traditional lipid
LE phase were seen in the films (bright regions (circle) in Fig.
5B). In this property the morphology of the system resembled
that of the films of SP-B and DPPC spread on SP-A2 (Fig. 4).
4. Discussion
Recent work has provided evidence for specific interaction
of the porcine proteins SP-A and SP-B in monolayers of lipids
[35,36]. The ability of monolayers containing SP-B to attract
SP-A into the surface were much greater than those containing
SP-C where little or no interaction with SP-A occurred [36,41].
The interaction between SP-B and SP-A was dependent on the
presence of lipid, especially phosphatidylcholine [36]. In this
paper, we investigated interactions between SP-B and in vitro
expressed SP-A1 and SP-A2 gene variants in the formation of
lipid monolayers in the presence of DPPC. The results, (a)
confirmed the interactions between SP-B and human SP-A from
alveolar proteinosis fluid in monolayers containing DPPC with
or without the presence of unsaturated PG; (b) showedFig. 3. Images from films of DPPC with SP-B (17%) spread over the product of
the 6A2 of SP-A1 (0.68 μg/ml). Surface pressures are given at the side of each
image. Panels A and B are from separate experiments. Both panels A and B
show three characteristic features typical for the monolayers: a fine network of
grey phase (block arrows) which extended throughout the LE phase, large
protein-rich patches (large dark grey regions, stars), and LC phase (small black
domains, arrows).
Fig. 4. Images from films of DPPC/SP-B (17%) spread over the product of the 1A0 of SP-A2 (0.68 μg/ml). Surface pressures are given at the side of each image. Panels
A and B are from separate experiments. The morphology of the films was very similar to that observed in the films containing combinations of SP-B and porcine SP-A
(Fig. 1A) or human SP-A (Fig. 1B).
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the two human SP-A genes. These differences were manifested
in the organizational states in the monolayer in which the SP-A
and SP-B complex is found; (c) the 1A0 variant of SP-A2
formed complexes similar to those seen before, with porcine
SP-A or with native human SP-A from alveolar proteinosis
fluid; (d) while the 6A2 variant from SP-A1 also formed a
surface complex, its organization and distribution differed from
that formed by native SP-As or by the 1A0 variant. In the case of
6A2, the complex observed was distributed in large patches and
an extensive network rather than in clusters in the LE phase asthey were when the 1A0 or native SP-A was present; (e)
coexpressed 1A0/6A2 SP-A showed a surface complex
formation with characteristics of both complexes (i.e. when
the 1A0 or 6A2 protein was used alone). These observations
indicate a differential impact of SP-A1 and SP-A2 products in
film formation and film regional organization including the
organization of film lipid-protein complexes that may influence
overall surface activity and other characteristics of the surface in
the lung.
The network formed, when the 6A2 product was present,
appeared to extend throughout the region of LE phase (that is
Fig. 5. Images of films of DPPC/SP-B (17%) spread over a coexpressed product (1A0/6A2) of SP-A1 and SP-A2 (0.68 μg/ml). Surface pressures are given at the
side of each image. Panels A and B are from different experiments. The morphology of the films containing SP-A1 and SP-A2 variants appears to combine
features of the lipid–protein monolayers containing SP-A1 (Fig. 3) and SP-A2 (Fig. 4). Large likely protein-rich patches (stars), similar to those seen in the
monolayers spread on SP-A1 (Fig. 3), and a network of grey phase (block arrows), similar to those seen in the monolayer spread on SP-A2 (Fig. 4), are observed
in the films containing SP-A1 and SP-A2.
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material was “dissolved” in the LE phase, but that the LE phase
provided a convenient (fluid) environment for the material to
form and lodge. While previous studies have shown that for
porcine SP-A the clustered complex formed contained both
SP-A and SP-B [36], this has not been shown definitively for
human SP-A and the SP-A variants. Nevertheless, it seems to
be a very reasonable assumption that all the grey phase
complexes seen in the monolayers described here containboth SP-A and SP-B. One cannot obtain a reliable estimate of
the extent of the phases with the current technology. Therefore,
one cannot tell if the extent or strength of interaction of SP-B
with one allelic product is different than with the other. Nor can
one tell the stoichiometry of the complexes. There is, however, a
remarkable difference observed in the shapes and locations of
the complexes in the monolayer.
Previous studies indicate that the two SP-Avariants (1A0 and
6A2) differ in six amino acid residues within the coding region
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precursor numbering are shown in the Table.Amino acid no. 19 66 73 81 85 91
1A0 Ala Thr Asn Val Arg Ala
6A2 Val Met Asp lle Cys ProRecent work has shown that removal of the signal peptide
results in molecules with various N-terminal sequences [26].
Some molecules may and others may not contain amino acid 19.
However, in either case, alanine and valine are relatively small
molecules and represent conservative amino acid differences,
and therefore it is unlikely that changes in amino acid 19 have a
major impact on SP-A function. The remaining amino acid
changes are located within the collagen-like domain of SP-A
and, as such, may play a role in the structural stability of SP-A
[24], or other functions [48–50].
We have shown previously that SP-A1 has a lower thermal
stability than SP-A2 [24] and suggested that this difference is
due to differences in amino acid 85. A cysteine at residue 85
may affect stability in the triple helix resulting in local micro-
unfolding. Studies on the stability of the tripeptide unit (Gly–
X–Y)n with different substitutions at the X and Y positions
have shown that the collagen triple-helix with guest triplets of
Gly–Glu–Arg had a higher stability than 40 other different
guest triplets tested [51,52]. We have also shown that in-vitro
expressed SP-A1 is identified with higher size oligomers than
SP-A2 [26], and speculated that amino acid 85 contributes to
oligomerization differences. Whether SP-A1 and SP-A2
differences, in the structural stability, oligomerization, or
both, contribute to the film differences observed in this study,
is currently unknown. However, recent findings from our
laboratory indicate that amino acid 85 plays indeed an
important role in characteristics that distinguish SP-A1 and
SP-A2 [53].
Moreover, differences in other biophysical and biochemical
properties have been observed between SP-A1 and SP-A2
[22,24,26]. These include self-aggregation, phospholipid and
lipopolysaccharide aggregation, differences in aggregation
and oligomerization pattern in response to ozone oxidation,
and others. The results described here extend the range of
differences between SP-A1 and SP-A2 products observed
previously in solution [24] to the influence of the SP-A1 and
SP-A2 variants on lipid monolayers containing SP-B. The
lipid–protein rearrangements caused by SP-A1 and SP-A2
seen in this work are consistent with the influence of these
products on aggregation [24] in that the SP-A2 product (1A0)
had a greater influence on the monolayers than did the SP-A1
product (6A2). Also, as in the previous observations in
solution [24] the SP-A2 product behaved more like native SP-
A in lipid–protein monolayers than did the SP-A1 product.
Functional differences between SP-A1 and SP-A2 in proin-
flammatory cytokine production [25,54], inhibition of surfac-
tant secretion [26], and ability of SP-A variants to enhance
phagocytosis [23,55] have also been observed. These
findings, along with the present observations indicate that
the properties and function of the SP-A1 (6A2) and SP-A2(1A0) differ, and the mechanisms through which these
contribute to diseases such as RDS [28,30–33] are likely to
differ. However, we speculate that a normally functioning
lung may depend on the relative levels of SP-A1 and SP-A2
and not the total levels of SP-A. Support for this postulate is
provided by our recent findings where the ratio of SP-A1 to
total SP-A differs as a function of lung health status [21].
In summary, this work indicates that differences in the nature
of physical interaction between SP-A variants with SP-B exist.
We speculate that these differences account for differences in
physiological properties of the surface monolayer, and therefore
an appropriate SP-A1 to SP-A2 content may be critical for lung
health. Additional work is necessary to understand more fully
the precise nature of these differences in physical properties and
their consequences for surfactant function.
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